{Reference Type}: Journal Article
{Title}: Diapocynin treatment induces functional and structural improvements in an advanced disease state in the mdx5Cv mice.
{Author}: Guedira G;Petermann O;Scapozza L;Ismail HM;
{Journal}: Biomed Pharmacother
{Volume}: 177
{Issue}: 0
{Year}: 2024 Jun 21
{Factor}: 7.419
{DOI}: 10.1016/j.biopha.2024.116957
{Abstract}: Duchenne muscular dystrophy (DMD) is the most common muscular disorder affecting children. It affects nearly 1 male birth over 5000. Oxidative stress is a pervasive feature in the pathogenesis of DMD. Recent work shows that the main generators of ROS are NADPH oxidases (NOX), suggesting that they are an early and promising target in DMD. In addition, skeletal muscles of mdx mice, a murine model of DMD, overexpress NOXes. We investigated the impact of diapocynin, a dimer of the NOX inhibitor apocynin, on the chronic disease phase of mdx5Cv mice. Treatment of these mice with diapocynin from 7 to 10 months of age resulted in decreased hypertrophy of several muscles, prevented force loss induced by tetanic and eccentric contractions, improved muscle and respiratory functions, decreased fibrosis of the diaphragm and positively regulated the expression of disease modifiers. These encouraging results ensure the potential role of diapocynin in future treatment strategies.